- Details
- Description
Packaging Size:
Varies by market and approved product presentation.
Strength:
Clinical studies have evaluated oral doses from 10–400 mg once daily; 300 mg once daily was selected as the Phase 3 dose in pancreatic cancer studies.
Composition:
Daraxonrasib (RMC-6236); molecular formula C₄₄H₅₈N₈O₅S.
Treatment:
Targeted anticancer therapy / RAS(ON) inhibitor for RAS-mutated solid tumors, including pancreatic cancer and certain RAS-mutated lung cancers.
Form:
Oral tablets.
Brand:
RASONQUE
Quantity Unit:
Tablets
Manufacturer:
Revolution Medicines, Inc. Н Национальный ин
Daraxonrasib (RMC-6236) is an oral, targeted anticancer drug designed to inhibit the active form of RAS proteins (RAS(ON)), which play a key role in tumor growth and survival. It is being investigated for the treatment of solid tumors driven by RAS mutations, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Daraxonrasib aims to block RAS signaling and thereby slow or prevent the proliferation of cancer cells.
